Nkarta NKTX 深 滬
等待開盤 10-08 09:30:00 美东时间
2.295
-0.015
-0.65%
華盛通- 最 高2.335
- 今 開2.26
- 成交量 27.80万股
- 最 低 2.25
- 昨 收 2.31
- 總市值 1.64亿
- 52周最高 3.72
- 市盈率 靜 --
- 換手率 0.39%
- 52周最低 1.70
- 委 比 53.61%
- 總股本 7162.48万
- 歷史最高 79.16
- 量 比 1.12
- 振 幅 3.68%
- 歷史最低 1.28
- 每 手 1
- 風險率 0.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nkarta to Participate in September Investor Conferences
Nkarta, Inc. announced its participation in two investor conferences: the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, in New York, and the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026. Both events will feature fireside chats and be webcast live on Nkarta’s website, with replays available for 90 days. Nkarta specializes in developing allogeneic NK cell therapies for autoimmune dise...
09-10 11:00
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
<p>Nkarta, Inc. announced three scientific presentations at ACR Convergence 2026, including two oral presentations on the safety and clinical activity of NKX019 in idiopathic inflammatory myopathy and overall autoimmune indications, and a poster presentation on its activity in systemic sclerosis. NKX019 is an allogeneic, CD19-targeted CAR NK-cell therapy being evaluated in autoimmune diseases. The presentations highlight its safety profile, preli...
09-08 11:00
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
HC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $14
HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $16 to $14.
08-11 20:34
Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 74.19 percent decrease over losses of $(0.31) per share from the same period last year.
08-11 05:04
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Nkarta, Inc. will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. Nkarta President Nadir Mahmood will discuss updates on the company’s investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases during a fireside chat at 2 p.m. ET. The discussion will be webcast live and available for replay on Nkarta’s investor website for 90 days. Nkarta is a clinical-stage biotech company developi...
06-26 12:45
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Needham Reiterates Buy on Nkarta, Maintains $11 Price Target
Needham analyst Gil Blum reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $11 price target.
05-13 18:45
